文献速递眼底病与葡萄膜炎

重度非增殖性糖尿病视网膜病变与增殖性糖尿病视网膜病变患眼超广角血管造影的视网膜无灌注特征

Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

该横断面图像分析研究基于英国两项随机临床试验的基线超广角血管造影图像,纳入92例(92眼)既往未接受全视网膜光凝的患眼,分析视网膜无灌注面积与增殖性病变的关系。研究发现视网膜无灌注阈值118.3个视盘面积对PDR的特异度为84.9%,增殖性改变眼无灌注面积中位数147.9 DA显著大于NPDR眼的67.8 DA,差异69.0 DA(P<.001)。作者认为无灌注至少107.3 DA的眼有增殖性疾病风险,且有NVD的眼无灌注面积最大。

要点

  • 视网膜无灌注阈值118.3 DA对PDR的特异度为84.9%(95%CI 68.1%至94.9%)。
  • 增殖性改变眼无灌注面积中位数147.9 DA,NPDR眼67.8 DA,差异69.0 DA(P<.001)。
  • 有NVD眼总无灌注面积最大,较仅有NVE眼差异65.1 DA(P<.001)。

核心结论

  • 这些发现提示无灌注至少107.3 DA的眼有增殖性疾病风险,且有NVD的眼视网膜无灌注面积最大。

研究设计与样本

  • 横断面图像分析研究,于2018年9月24日至2018年10月24日在英国一项多中心全国性研究中开展。
  • 基线图像来自2项已完成的随机临床试验:RDP研究(2014年4月1日至2015年12月31日招募重度NPDR眼)和CLARITY研究(2014年8月22日至2015年11月20日招募PDR眼)。
  • 纳入既往未接受全视网膜光凝治疗的患眼超广角血管造影图像,共92例患者(92眼),PDR组59眼(平均[SD]年龄42[15]岁;女性20例[33.9%]),NPDR组33眼(平均[SD]年龄63[10]岁;女性3例[9.1%])。
  • 40眼有NVE,19眼有NVD伴或不伴NVE。

主要发现

  • 视网膜无灌注阈值118.3个视盘面积(DA)对PDR的特异度为84.9%(95%CI 68.1%至94.9%)。
  • 视网膜无灌注面积中位数在NPDR眼为67.8 DA(95%CI 44.2至107.3 DA),在增殖性改变眼为147.9 DA(95%CI 127.4至173.5 DA),差异69.0 DA(95%CI 42.2至97.7 DA;P<.001)。
  • 后极部无灌注面积中位数在NPDR与PDR之间无差异,差异0 DA(95%CI -6.7至5.2 DA;P=.56)。
  • 周边部无灌注面积NPDR眼为64.1 DA,PDR眼为130.6 DA,差异70.8 DA(95%CI 48.4至94.9 DA;P<.001)。
  • 有NVD眼总视网膜无灌注面积最大,与仅有NVE眼相比差异65.1 DA(95%CI 28.6至95.8 DA;P<.001)。

关键数值与推荐

  • 视网膜无灌注阈值118.3 DA对PDR的特异度为84.9%(95%CI 68.1%至94.9%)。
  • 作者认为无灌注至少107.3 DA的眼有增殖性疾病风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Threshold of retinal nonperfusion for the development of proliferative diabetic retinopathy (PDR) is unclear. OBJECTIVES: To identify a threshold of retinal nonperfusion for the presence of retinal neovascularization and the distribution and area of retinal nonperfusion in eyes with severe nonproliferative diabetic retinopathy (NPDR), PDR, neovascularization of the optic disc (NVD), and retinal neovascularization elsewhere (NVE). DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional image analysis study was performed between September 24, 2018, and October 24, 2018, at a multicenter national study in the United Kingdom. Baseline images were obtained from 2 completed randomized clinical trials (Ranibizumab for Diabetic Macular Edema Panretinal Photocoagulation [RDP] study and Clinical Efficacy of Intravitreal Aflibercept vs Panretinal Photocoagulation for Best Corrected Visual Acuity in Patients With Proliferative Diabetic Retinopathy at 52 Weeks [CLARITY] study). The RDP study recruited eyes with severe NPDR between April 1, 2014, and December 31, 2015, and the CLARITY study recruited eyes with PDR between August 22, 2014, and November 20, 2015. Ultra-widefield angiography images of eyes with no prior panretinal photocoagulation treatment were included. MAIN OUTCOMES AND MEASURES: The total area of retinal nonperfusion, the area of posterior pole retinal nonperfusion, and the area of peripheral retinal nonperfusion were measured. RESULTS: A total of 92 patients (92 eyes) were included in the study: 59 in the PDR group (mean [SD] age, 42 [15] years; 20 female [33.9%]) and 33 in the NPDR group (mean [SD] age, 63 [10] years; 3 female [9.1%]). Forty eyes had NVE and 19 had NVD with or without NVE. We identified a retinal nonperfusion threshold of 118.3 disc areas (DA) with a specificity of 84.9% (95% CI, 68.1% to 94.9%) for PDR. The median area of retinal nonperfusion was 67.8 DA (95% CI, 44.2 to 107.3 DA) in the NPDR eyes and 147.9 DA (95% CI, 127.4 to 173.5 DA) for eyes with proliferative changes, with a difference of 69.0 DA (95% CI, 42.2 to 97.7 DA; P < .001). No difference was found in the median area of posterior nonperfusion between NPDR and PDR, with a difference of 0 DA (95% CI, -6.7 to 5.2 DA; P = .56). As for peripheral nonperfusion, NPDR eyes measured 64.1 DA and PDR eyes measured 130.6 DA, with a difference of 70.8 DA (95% CI, 48.4 to 94.9 DA; P < .001). Eyes with NVD had the largest total area of retinal nonperfusion, with a difference of 65.1 DA (95% CI, 28.6 to 95.8 DA; P < .001) compared with eyes with only NVE. CONCLUSIONS AND RELEVANCE: These findings suggest eyes with at least 107.3 DA of nonperfusion are at risk of proliferative disease, and eyes with NVD have the largest area of retinal nonperfusion.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nicholson L, Ramu J, Chan EW, et al. Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2019. PMID: 30973596. doi:10.1001/jamaophthalmol.2019.0440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。